Strong Momentum Drives Venus Remedies to New Heights
On 27 Nov 2025, Venus Remedies recorded an intraday peak of Rs.757, marking both a fresh 52-week and all-time high for the stock. This price level represents a significant advance from its 52-week low of Rs.272.20, highlighting a remarkable trajectory over the past year. The stock has been on a positive run for the last two consecutive days, delivering a cumulative return of 10.32% during this period.
Today's trading session saw Venus Remedies outperform its sector by 7.14%, reflecting stronger relative strength within the Pharmaceuticals & Biotechnology space. The stock exhibited notable volatility, with an intraday weighted average price volatility of 5.3%, indicating active trading interest and dynamic price movement throughout the day.
Technical indicators support the bullish trend, as Venus Remedies is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This alignment of moving averages often signals sustained upward momentum and investor confidence in the stock’s near-term prospects.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
See What's Driving the Rally →
Market Context and Comparative Performance
The broader market environment has also been supportive. The Sensex opened 135.54 points higher and reached a new 52-week high of 85,934.80, reflecting a 0.38% gain on the day. The index is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling a bullish market trend. Over the past three weeks, the Sensex has recorded a 3.27% rise, led by gains in mega-cap stocks.
Against this backdrop, Venus Remedies’ one-year performance stands out distinctly. The stock has delivered a return of 141.15% over the last 12 months, significantly outpacing the Sensex’s 7.12% return during the same period. This substantial outperformance highlights the company’s strong growth trajectory relative to the broader market.
Financial Metrics Underpinning the Rally
Venus Remedies’ recent financial disclosures provide insight into the factors supporting its price appreciation. The company reported a net profit after tax (PAT) of Rs.20.13 crores for the latest quarter, reflecting a growth of 473.5%. This marks the fourth consecutive quarter of positive results, underscoring consistent profitability improvements.
Return on Capital Employed (ROCE) for the half-year period reached 13.99%, the highest recorded by the company, indicating efficient utilisation of capital resources. Additionally, the inventory turnover ratio stood at 6.58 times, signalling effective inventory management and operational efficiency.
Venus Remedies maintains a low average debt-to-equity ratio of zero, reflecting a conservative capital structure with minimal leverage. This financial prudence contributes to the company’s attractive valuation metrics, including a price-to-book value of 1.6 and a return on equity (ROE) of 10.5%, which are favourable compared to sector peers.
Get the full story on Venus Remedies ! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this Pharmaceuticals & Biotechnology micro-cap. Make informed decisions!
- - Full research story
- - Sector comparison done
- - Informed decision support
Long-Term Growth and Valuation Insights
Over the longer term, Venus Remedies has demonstrated market-beating performance. The stock has outperformed the BSE500 index over the last three years, one year, and three months, reflecting sustained growth and investor confidence. Profit growth over the past year has been recorded at 183%, reinforcing the company’s strong earnings momentum.
The company’s PEG ratio of 0.1 suggests that the stock’s price is supported by its earnings growth, indicating a valuation that is reasonable relative to its growth rate. This balance between growth and valuation has contributed to the stock’s upward trajectory and the achievement of its new 52-week high.
Considerations on Shareholding Patterns
Despite the company’s size and performance, domestic mutual funds currently hold no stake in Venus Remedies. This absence may reflect a cautious stance or differing views on valuation within certain institutional circles. However, the stock’s recent price action and financial metrics provide a clear picture of its current market standing.
Summary
Venus Remedies’ attainment of a new 52-week high at Rs.757 marks a significant milestone in its market journey. Supported by strong quarterly profits, efficient capital utilisation, and favourable valuation metrics, the stock has demonstrated robust momentum. Its performance notably surpasses broader market indices, reflecting the company’s growing prominence within the Pharmaceuticals & Biotechnology sector.
The current market environment, characterised by a rising Sensex and positive sector trends, has further bolstered Venus Remedies’ price movement. Trading above all key moving averages and exhibiting strong relative strength, the stock’s recent rally highlights a period of sustained investor interest and operational progress.
Investors and market participants will continue to monitor Venus Remedies as it navigates this elevated price territory, with its financial fundamentals and market positioning providing a solid foundation for its current valuation.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
